Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
Summary
This is a study in which pancreatic cancer patients receive a combination therapy with CART-meso cells and CART19 cells administered at 3 days after one dose of cyclophosphamide. CART-meso cells are patients' own T cells that were modified in the laboratory to express a receptor specific to the mesothelin protein. CART19 cells are patients' own T cells that were modified in the laboratory to express a receptor specific to a protein called CD19. The CD19 protein is expressed on white blood B cells. CART19 cells are expected to attack the B cells and impede the antibody response against CART-meso cells. The investigators hypothesize that this combination therapy may prolong the duration of CART-meso cells in the body. Additionally, one dose of cyclophosphamide may enhance engraftment and persistence of CART cells.
Timeline
- Start
- 2015-05
- Primary completion
- 2017-09
- Completion
- 2017-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CART-meso | Cell therapy | 1e+07 cells | Intravenous |
| Subject | CART-meso | Cell therapy | 1e+08 cells | Intravenous |
| Subject | Tisagenlecleucel | Cell therapy | 1e+07 cells | Intravenous |
| Subject | Tisagenlecleucel | Cell therapy | 1e+08 cells | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 1.5 g | — |